Cosunter(SZ:300436) Chang Jiang Shang Bao·2025-09-02 23:49Core Viewpoint - Guangshentang's subsidiary, Guangsheng Zhonglin, is introducing external investors through a capital increase and equity transfer, raising a total of 250 million yuan, marking a significant step in its ongoing transformation into an innovative pharmaceutical company [1][2]. Group 1: Investment Details - Guangsheng Zhonglin's pre-investment valuation is set at 2.5 billion yuan, reflecting a 25% increase from the previous round [1][4]. - The investment will be conducted in two phases, with Jinan Taishen and Huaxin Shiheng investing 141 million yuan and 50 million yuan respectively, while also acquiring equity from existing shareholders [2][3]. - The total transaction amount of 250 million yuan will enhance Guangsheng Zhonglin's capital strength and support its ongoing research and development efforts [1][5]. Group 2: Financial Performance - Since its IPO in 2015, Guangshentang has faced continuous losses, with a cumulative net loss of 734 million yuan from 2021 to the first half of 2025 [1][8]. - Guangsheng Zhonglin reported revenues of 28.9 million yuan and 8.01 million yuan for 2024 and the first half of 2025, respectively, with net losses of 85.43 million yuan and 19.66 million yuan [1][8]. - The company has been investing heavily in R&D, with a reported R&D expense of 15.87 million yuan in the first half of 2025, a decrease of 14.31% year-on-year [7][8]. Group 3: Strategic Focus - Guangsheng Zhonglin is positioned as the innovative drug development platform for Guangshentang, focusing on high-investment, long-cycle drug development tasks [5][6]. - The company aims to accelerate the development of innovative drugs, including treatments for non-alcoholic fatty liver disease and liver fibrosis, through this capital infusion [5][6]. - Guangshentang is also pursuing a new round of financing to further enhance its innovative drug development efforts, with plans to raise up to 977 million yuan [8].